A. Berruti, E. Baudin, H. Gelderblom, H. Haak, F. Porpiglia et al., Pentheroudakis 416 G Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly et al., Combination chemotherapy in advanced adrenocortical carcinoma, N. Engl. J, p.425

A. Berruti, M. Fassnacht, E. Baudin, G. Hammer, H. Haak et al., Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel, Journal of Clinical Oncology, vol.28, issue.23, pp.401-402, 2010.
DOI : 10.1200/JCO.2009.27.5958

T. Else, A. Williams, A. Sabolch, S. Jolly, B. Miller et al., Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.455-461, 2014.
DOI : 10.1210/jc.2013-2856

F. Mantero, B. Allolio, L. Dogliotti, and A. Berruti, Adjuvant mitotane treatment for adrenocortical 436 carcinoma, N. Engl. J. Med, vol.356, issue.23, pp.2372-2380, 2007.

H. Haak, J. Hermans, C. Van-de-velde, E. Lentjes, B. Goslings et al., Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients, British Journal of Cancer, vol.69, issue.5, pp.947-951, 1994.
DOI : 10.1038/bjc.1994.183

E. Baudin, G. Pellegriti, M. Bonnay, A. Penfornis, A. Laplanche et al., Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p?DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, vol.62, issue.6, pp.1385-1392, 2001.
DOI : 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2

S. Lindstedt, A. Odén, and H. Ahlman, The long-term survival in adrenocortical carcinoma with 450 active surgical management and use of monitored mitotane, Endocr. Relat. Cancer, vol.45117, issue.1, pp.265-272, 2010.

I. Hermsen, M. Fassnacht, M. Terzolo, S. Houterman, J. Den-hartigh et al., Plasma Concentrations of o,p???DDD, o,p???DDA, and o,p???DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.6, pp.1844-1851, 2011.
DOI : 10.1210/jc.2010-2676

H. Van-slooten, A. Moolenaar, A. Van-seters, and D. Smeenk, The treatment of adrenocortical 458 carcinoma with o,p'-DDD: prognostic implications of serum level monitoring, Eur J Cancer, vol.459

D. Gebhardt, A. Moolenaar, A. Van-seters, E. Van-der-velde, G. Leuven et al., The distribution ofo,p???-DDD (Mitotane) among serum lipoproteins in normo- and hypertriglyceridemia, Cancer Chemotherapy and Pharmacology, vol.51, issue.Suppl, pp.331-334, 1992.
DOI : 10.1007/BF00685956

V. Maher, P. Trainer, A. Scoppola, J. Anderson, G. Thompson et al., Possible 464 mechanism and treatment of o,p'DDD-induced hypercholesterolaemia, Q. J. Med. 465, vol.84, issue.305, pp.671-679, 1992.

D. Gebhardt, A. Moolenaar, and A. Van-seters, Mitotane (o,p???-DDD) Administration Raises the Serum Level of High Density Lipoprotein (HDL) in Normotriglyceridemia, Hormone and Metabolic Research, vol.25, issue.04, pp.240-241, 1993.
DOI : 10.1055/s-2007-1002086

A. Termine, D. Carlo, F. Dogliotti, L. Angeli, A. Berruti et al., Prospective evaluation 476 of mitotane toxicity in adrenocortical cancer patients treated adjuvantly, Endocr. Relat. Cancer, vol.47715, issue.4, pp.1043-1053, 2008.

H. Shawa, F. Deniz, H. Bazerbashi, M. Hernandez, R. Vassilopoulou-sellin et al., Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study, International Journal of Endocrinology, vol.143, issue.11, pp.624962-481, 2013.
DOI : 10.1186/1476-511X-10-181

P. Stacpoole, C. Varnado, and D. Island, Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme a reductase activity by o,p???-DDD, Biochemical Pharmacology, vol.31, issue.5, pp.857-860, 1982.
DOI : 10.1016/0006-2952(82)90474-9

R. Moy, Studies of the pharmacology of o,p'DDD in man, J. Lab. Clin. Med, vol.58, pp.296-484, 1961.

A. Ghuzlan, J. Young, E. Baudin, and M. Lombès, The lack of antitumor effects of o,p'DDA 487 excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment, Horm Cancer, vol.4885, issue.5, pp.312-323, 2014.

N. Kaminsky, S. Luse, and P. Hartroft, Ultrastructure of adrenal cortex of the dog during treatment 490 with DDD, J. Natl. Cancer Inst, vol.29, pp.127-159, 1962.

M. Luconi, Morpho-functional effects of mitotane on mitochondria in human adrenocortical 493 cancer cells, Endocr. Relat. Cancer, 2013.

L. Amazit, J. Young, E. Baudin, and M. Lombès, Mitotane alters mitochondrial respiratory chain 496 activity by inducing cytochrome c oxidase defect in human adrenocortical cells, Endocr. Relat. 497 Cancer, vol.20, issue.3, pp.371-381, 2013.

S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar et al., New response evaluation criteria in solid tumours: revised RECIST guideline 501 (version 1.1), Eur. J. Cancer, vol.45, issue.2, pp.228-247, 2009.

D. Chretien, P. Bénit, M. Chol, S. Lebon, A. Rötig et al., Assay of 503 mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts, p.504

M. Guérin, E. Bruckert, P. Dolphin, G. Turpin, and M. Chapman, Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.16, issue.6, pp.763-772, 1996.
DOI : 10.1161/01.ATV.16.6.763

R. Pohland and R. Counsell, The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat, Toxicology and Applied Pharmacology, vol.77, issue.1, pp.47-57, 1985.
DOI : 10.1016/0041-008X(85)90266-2